Riamilovir sodium hydrate

Riamilovir, also known as Triazavirin, is an antiviral drug candidate. Tiazavirin is a broad-spectrum antiviral drug developed in Russia. It has a novel triazolotriazine core, which represents a new structural class of non-nucleoside antiviral drugs. It was originally developed as a potential treatment for pandemic influenza strains such as H5N1, and most of the testing that has been done has focused on its anti-influenza activity. However triazavirin has also been found to have antiviral activity against a number of other viruses including Tick-borne encephalitis virus, and Forest-Spring Encephalitis virus, and is also being investigated for potential application against Lassa fever and Ebola virus disease. In February 2020, testing of triazavirin was started against SARS-CoV-2.

Product information

CAS Number: 928659-17-0

Molecular Weight: 310.20

Formula: C5H8N6Na2O5S

Synonym:

Riamilovir

Triazavirin

TZV

Riamilovir sodium hydrate

Chemical Name: 7-(Methylthio)-3-nitro-[1,2,4]triazolo[5,1-c][1,2,4]triazin-4(6H)-one sodium sodium dihydrate

Smiles: O.O.[Na].[Na].CSC1NN2C(N=1)=NN=C(C2=O)[N+]([O-])=O |^1:2,3|

InChiKey: RPBLQPMOBSLKTG-UHFFFAOYSA-N

InChi: InChI=1S/C5H4N6O3S.2Na.2H2O/c1-15-5-6-4-8-7-2(11(13)14)3(12)10(4)9-5;;;;/h1H3,(H,6,8,9);;;2*1H2

Technical Data

Appearance: Solid Power.

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: Soluble in DMSO

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined.

HS Tariff Code: 382200

How to use

In Vitro:

The efficacy of Triazavirin against the tick-borne encephalitis virus is estimated in the sensitive cell culture. In a concentration of 128 mcg/mL Triazavirin is shown active in inhibition of the tick-borne encephalitis virus reproduction (strain Sofiin) by accumulation in the SKEV cell culture.

In Vivo:

The therapeutic efficacy Triazavirin against experimental Forest-Spring encephalitis on albino mice is studied. The results shows that in high doses (200-400 mg/kg) Triazavirin moderately protects the infected animals. A significant increase of the animal lifespan in the test groups (from 4.1 to 4.8 days) and a statistically valid decrease of the virus accumulation in the target organ are observed.

References:

1. Shahab S, Sheikhi M. Triazavirin - Potential inhibitor for 2019-nCoV Coronavirus M protease: A DFT study. Curr Mol Med. 2020 May 20. doi: 10.2174/1566524020666200521075848. Epub ahead of print. PMID: 32436829.

Products are for research use only. Not for human use.